Ocular toxicities of fibroblast growth factor receptor inhibitors: A review
-
Published:2024-01
Issue:1
Volume:69
Page:34-41
-
ISSN:0039-6257
-
Container-title:Survey of Ophthalmology
-
language:en
-
Short-container-title:Survey of Ophthalmology
Author:
Hsu JerryORCID,
Francis Jasmine H.,
Ahmad SumayyaORCID
Reference71 articles.
1. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study;Abou-Alfa;Lancet Oncol,2020
2. Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: the SAKK 19/18 phase II study;Addeo;Lung Cancer,2022
3. SWOG S1400D (NCT02965378), a phase II study of the fibroblast growth factor receptor inhibitor AZD4547 in previously treated patients with fibroblast growth factor pathway-activated stage IV squamous cell lung cancer (Lung-MAP Substudy);Aggarwal;J Thorac Oncol,2019
4. Multifocal serous retinopathy with pemigatinib therapy for metastatic colon adenocarcinoma;Alekseev;Int J Retina Vitreous,2021
5. Multicenter phase I study of erdafitinib (JNJ-42756493), oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced or refractory solid tumors;Bahleda;Clin Cancer Res,2019